netFormulary NHS
South Staffordshire Joint Formulary
Cannock Chase Clinical Commissioning Group
East Staffordshire Clinical Commissioning Group
South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group
Stafford and Surrounds Clinical Commissioning Group
 Search
 Results

Looking for Alemtuzumab found 4 matches
Open monograph to display formulary status BNF Category
  Alemtuzumab  (MabCampath®) Malignant disease and immunosuppression - Anti-lymphocyte monoclonal antibodies - 08.02.03
  Ocrelizumab  (Ocrevus®) Malignant disease and immunosuppression - Anti-lymphocyte monoclonal antibodies - 08.02.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA202: Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (08.02.03)
link in drug section NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis (08.02.03)


 
netFormulary